Abstract:Introduction The CHADS-P2A2RC score has been developed to provide better prognostic precision and improved selection of at-risk patients with coronary artery disease (CAD). The linkage of this clinical ischemic risk with thrombogenicity and their prognostic implication remain still unknown. Purpose We investigated the values of thrombogenicity indices according to the CHADS-P2A2RC score and their combined prognostic prediction in CAD patients undergoing percutaneous coronary intervention (PCI). Methods In PCI-treated patients (PCI) (n=2,705), clinical ischemic risk was classified with CHADS-P2A2RC score ("high risk": ≥ 4) and thrombogenicity indices were assessed using thromboelastography (TEG). Major adverse cardiovascular events (MACEs: a composite of all-cause death, myocardial infarction, or stroke) and major bleeding were evaluated were monitored for up to 3 years. Results Compared with "low/moderate-risk group" (67.7%), "high-risk group" (32.3%) had higher platelet-fibrin clot strength (PFCS: 67.3±7.9 vs. 65.2±7.2 mm; P < 0.001) and lower fibrinolytic activity (clot lysis at 30 min [LY30]: 0.9±2.1% vs. 1.1±2.4%, P < 0.001]. The "high-risk group" showed higher rates of "high PFCS phenotype (≥ 68 mm)" (35.3% vs. 49.7%; P <0.001), MACE (HRadjusted: 1.47; 95% CI: 1.01-2.13; P = 0.045) and all-cause mortality (HRadjusted: 1.87; 95% CI: 1.14-3.07; P = 0.013) than the "low/moderate-risk group", respectively. Among the "low/moderate-risk group", "high MA phenotype" independently predicted MACE (HRadjusted: 1.51; 95% CI: 1.00-2.27; P = 0.048) and all-cause mortality (HRadjusted: 1.90; 95% CI: 1.06-3.4; P = 0.031). Likewise, this phenotype increased the risks of MACE (HRadjusted: 1.47; 95% CI: 1.01-2.13; p = 0.045) and all-cause mortality (HRadjusted: 1.87; 95% CI: 1.14-3.07; p = 0.013) in the "high-risk group" (Table 1 and Figure 1). Prognostic impact of "high MA phenotype" on major bleeding was not significantly different across the risk-group (HRadjusted: 1.02; 95% CI: 0.39-2.72; P = 0.963 in the "low/moderate-risk group" and HRadjusted: 1.08; 95% CI: 0.50-2.34; P = 0.884 in the "high-risk group", respectively). Conclusion In PCI-treated patients, CHADS-P2A2RC score was significantly associated with a worse clinical outcome and more thrombogenic profile. Regardless of the ischemic-risk group, the level of clot-strength had an addictive effect on predicting the risk of ischemic event, indicating assessment of thrombogenicity indices using TEG may enhance post-PCI risk stratification for personalized antithrombotic therapy.

Related predictors of long term hemorrhagic events post-CABG antiplatelet therapy

The predictive value of thrombelastography system on thromboembolic and bleeding events in Chinese aged people-receiver operating characteristic analysis

Thromboelastography predicts dual antiplatelet therapy-related hemorrhage in patients with acute ischemic stroke

Does Thromboelastography Predict Bleeding in Patients Treated with Clopidogrel or Ticagrelor in Off-Pump Coronary Artery Bypass Grafting?

Platelet reactivity by thromboelastography in patients undergoing percutaneous coronary intervention

Triglyceride Glucose Body Mass Index as 3 Year Prognostic Indicator for Major Adverse Cardiovascular and Cerebrovascular Events in Patients with Acute Myocardial Infarction After PCI: A Prospective Cohort Study

Predicting Hemorrhage and Obstruction in the Elderly Population Using Thromboelastographic Indices.

Platelet-fibrin Clot Strength Measured by Thromboelastography Could Predict Hypercoagulability and Antiplatelet Effects in Patients after Percutaneous Coronary Intervention.

Prognosis prediction of thrombelastography in patients undergoing percutaneous coronary intervention

Gamma-Glutamyl Transferase-to-Platelet Ratio as a Novel Predictor of Long-Term Adverse Outcomes in Patients after Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study

Clinical usefulness of thrombelastograph in patients with acute coronary syndrome

Association between clinical ischemic risk and thrombogenicity phenotype and their prognostic prediction in patients undergoing percutaneous coronary intervention

Construction and validation of risk prediction model for gastrointestinal bleeding in patients after coronary artery bypass grafting

Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.

Residual Platelet Reactivity is Preferred over Platelet Inhibition Rate in Monitoring Antiplatelet Efficacy: Insights Using Thrombelastography

Predictive accuracy of diagnostic tests for excessive bleeding in cardiac surgery: the COPTIC-C study

Association Between Thrombelastography System and Vascular Obstructions and Hemorrhage: a Two-Year Follow-Up Study of Elderly Chinese Patients.

MiR-223 Levels Predicting Perioperative Bleeding in Off-Pump Coronary Artery Bypass Grafting

The Latest Cutoff Value of High-Sensitivity Cardiac Troponin I (access Hs-Tni) for Major Adverse Cardiac Events During the Perioperative Period of Coronary Artery Bypass Grafting: a Retrospective Study from a Single Heart Center

Analysis of TEG changes on 72 cases of perioperative coronary artery bypass grafting

Hemorrhagic risk prediction in coronary artery disease patients based on photoplethysmography and machine learning